D iscoveliesearch Inc.
You may qualify for a clinical research study if you have any
of the following conditions:
NECK OR BACK PAIN
• Recent onset of muscle pain in the neck
or back with spasm (involuntary contraction)
• Must be 18 to 75 years of age
• Up to $ 100 paid for time and travel
FACIAL ACNE
• Male and Female 12 years of age and older
• Have mild to moderate facial acne
• Reimbursement for time and travel
(979)776-1417, or toll free (888)436-9586
Medical assessments, study-related diagnostic tests, and investigational
medication are provided to qualified participants at no charge.
Butter Scores Better Schools
ClassSize-8 LSAT
Classes Starting Soon!
• Maximum of eight students in a class
- Earpert, enthusiastic instructors
■ Free extra help with your instructor
■ Guaranteed satisfaction
Last chance to prep for the October LSAT!
www.PnncetonReview.com | 800-2Review
IfcAT Jo a (■«*}!«trod tri»a*mork ol thu Law School Acimteaon Council O-SAC).
Thn Prlncwon HikJiiw It not vWih Prinorton Univwriry or LOAC.
6
STATE
Wednesday, February 26, 2003
THE BATTALI05
Saddam says he won’t go into
exile, no relation to al-Qaida
By Bassem Mroue
THE ASSOCIATED PRESS
BAGHDAD, Iran 0 — Iraqi leader
Saddam Hussein says he would rather die
than leave his country, dismissing recent
arguments by U.S. and Arab leaders that
he could go into exile to avoid war.
“We will die here. We will die in this
country and we will maintain our honor —
the honor that is required ... in front of our
people,” Saddam says in an interview with
CBS’ Dan Rather.
The network reported excerpts of the
interview on its Web site Tuesday night,
and said the comments would air
Wednesday on “60 Minutes II.”
“Whoever decides to forsake his nation
from whoever requests is not true to the
principles,” Saddam says. “I believe that
whoever ... offers Saddam asylum in his
own country is in fact a person without
morals.”
President Bush said last month that he
would welcome Saddam Hussein going
into exile and some Arab countries, most
notably Saudi Arabia, have proposed offer
ing Saddam exile to avoid a war.
Saddam also denied any links to Osama
bin Laden or al-Qaida and indicated he
would not set fire to Iraq’s oil fields or
destroy its dams if a U.S.-led invasion
occurs in Iraq.
“Iraq does not burn its wealth and it
does not destroy its dams,” Saddam says.
He said that Iraq has never had any rela
tionship to al-Qaida terrorists, “and I think
that Mr. bin Laden himself has recently, in
one of his speeches, given such an answer
that we have no relation with him.”
In a part of the interview that aired ear
lier Tuesday on CBS, the Iraqi president
indicated he wouldn’t heed a U.N. demand
to destroy Iraq’s A1 Samoud 2 missiles and
said his missiles didn’t exceed ranges
allowed by the United Nations.
But Iraq’s deputy prime minister, Tariq
Aziz insisted Tuesday that the government
had not yet decided whether to destroy its
A1 Samoud 2 missiles. “It’s being stud
ied,” Aziz said.
“Readiness for the aggression is con
tinuing ... but this doesn’t mean that we
should stop our political and diplomatic
work,” Aziz said. “We should continue
with it, but we should also prepare our
selves for the battle.”
Both Iraqi and U.N. officials spoke of
new, substantive cooperation. U.N. inspec
tors visited a pit where Iraq says it
destroyed biological weapons in 1991, and
Iraq reported finding an R-400 bomb con
taining liquid at a disposal site.
“We have made some progress. In fact,
we have made some breakthroughs,” said
Lt. Gen. Amer al-Saadi, Saddam’s adviser
on the inspections.
Iraq appeared to be sending conflicting
messages over an order from chief
weapons inspector Hans Blix to destroy its
A1 Samouds and their components by the
end of the week because the missiles cai
fly farther than allowed.
The missiles are still being produced
and tested, the inspectors’ spokesman in
Baghdad, Hiro Ueki, said Tuesday. He said
the last test took place Monday.
Al-Saadi also said Iraq was still study
ing the U.N. missile order. He said le
would not comment on the Saddam inter
view because he had not seen it.
Ueki said at a news conference thattk
United Nations was still awaiting an ol-
cial response on the missiles.
He said inspectors have completed tag
ging all deployed A1 Samoud 2 missiles
but still needed to tag some unassembled
components.
Ueki also said inspectors havebegunto
visit excavations by the Iraqis southeast of
Baghdad at a site where Iraq says it
destroyed bombs filled with biological
agents in 1991. On Monday and Tuesday
inspectors examined munitions fragments
around the pit, he said.
U.S. warplanes, meanwhile, bombed
missile launch systems in northern and
southern Iraq on Tuesday because they
threatened coalition forces enforcing no-
fly zones, the U.S. military said.
U.S. and British planes have beet
enforcing no-fly zones in north and soul
Iraq since the 1991 Gulf War. They are
intended to protect minority Kurds in the
north and Shiite Muslims in the south from
Iraqi government forces.
/fyi
ou need someone to tgfk to... Mentors g re there to listen.
Mentors in the College of Business
Dr. Stanley Kratchman
Dr. L. Murphy Smith
Dr. Robert Strawser
Finance
Mr. Ed Elmore
Dr. John Groth
Dr. Lawrence Wolken
Info and Operations Management
Mr. Paul Ammons
Ms. Louise Darcey
Retailing Studies
Mrs. Cindy Billington
Marketing
Dr. Stephen McDaniel
Mentors in the College of Architecture
Construction Science
Dr. David Bilbo
Dr. Charles Graham
Dr. Nancy Holland
Landscape Architecture and
Urban Planning
Dr. Donald Sweeney
Ms. Nancy Volkman
Graduate Programs Office
Ms. Jill Raupe
Ms. Stephanie Matlock
Management
Dr. Michael Abelson
Mr. Ed Elmore
Ms. Kristi Mora
Mr. Keith Swim
Undergraduate Programs
Ms. Myra Gomez
Dr. Linda W indie
Undergraduate Programs Office
Mr. James Fancis. Jr
£
•6
•ft
•ft
•ft
•ft
•ft
•ft
•ft
•ft
•ft
ftr
■ft
■ft
■ft
•ft
ftr
ft?
ft?
ft?
■ft
ft?
•ft
-ft
ft?
ft?
ft?
ft?
ft?
ft?
ft?
ft?
ft?
ft?
ft?
Executive Development
Dr. Ben Welch
Dean's Office
Ms. Lara Zuehlke
Accounting
Dr. Lorence Bravenec
Dean ’s Office
Ms. Venesa Ann Flores
Architecture
Mr. Rodney Hill
Dr. Mardelle Shepley
Dr. Guillermo Vasquez
de Velasco
Dean's Office
Ms. Cathy Littleton
Dr. Mary Richardson
Mentors in the College of Geosciences
Atmospheric Sciences
Mr. Marion Alcom
Geography
Dr. Robert Bednarz
Ms. Debra Davis
Geology and Geophysics
Dr. J. Rick Giardino
Dr. Andrew Hajash
Dr. Christopher Mathewson
Dr. Honebin Zhan
Oceanography
Dr. William Bryant
Dr. William Sager
Dr. Niall Slowey
Mentors die faculty, staff, and ddministration dedicated to helping students.
Visit out website at http://mcntoi-s.tamu.edu for more information on these and other Mentors!
ft'ftrft?'ftr-ft'-ft'ftr-ft'-ft'ftr , ft'-ft'ftrftr^ftrftrftrft?--ft'-ft'ftr-ftrftrftrftrftrftrftrftrftrft?'ftr^ft'ftr-ft-ftr-ft''ft'ftr-ft'ft?'ftrftrftrftrftrftrftr
Senator files bill to change
public education funding
AUSTIN — The state would
fund teacher salaries and bene
fits and local school districts
would pay for textbooks and
other costs under legislation
proposed Tuesday by a state
senator.
A measure by Sen. Kyle
Janek, R-Houston, would repeal
the current school finance sys
tem, known by some as “Robin
Hood.” It would replace it with
a system that lifts Texas teacher
salaries to the national average
and provides teachers with a
“generous benefits package,”
Janek said.
School districts would set the
actual salary level of each
teacher based on experience.
“My bill would clarify what
the state pays for and what local
districts pay for,” Janek said in
a statement. “This will dramati
cally alter the balance of school
funding, with the state picking
up the majority of the tab.”
There was no estimate on the
cost to the state.
Parts of the proposal would
require voter approval.
The existing share-the-
wealth school finance system is
based heavily on local propert;
taxes. It gives schools in proper
ty-poor areas money from
wealthier districts.
Many property-rich districis
have reached the legal tax limit
and complain that they are
unable to raise more moneyAr
their schools.
Janek’s proposal would toe
schools funded based on the
number of teachers per district,
using the national average of
teacher salaries as a basis. Tb(
state formula would be one
teacher for every 20 students foi
all grade levels.
Under the proposal, the stale
would continue its facilities pro
gram that helps property-poo:
school districts construct build
ings through matching funds.
School districts would si
impose property taxes — and
would still have a $1.50 proper
ty tax cap — to pay for suck
expenses as administration,
books, buses and building
under Janek’s plan.
i.ja.i.Bdj.wggi
Contraceptive Injection
medroxyprogesterone acetate injectable suspension
DEPO-PROVERA 0 Contraceptive Injection
(medroxyprogesterone acetate injectable suspension, USP)
This product is intended to prevent pregnancy. It does not protect against HIV
infection (AIDS) and other sexually transmitted diseases.
What is DEPO-PROVERA Contraceptive Injection?
DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an
intramuscular injection (a shot) in the buttock or upper arm once every 3 months (13 weeks). To
continue your contraceptive protection, you must return for your next injection promptly at the
end of 3 months f 13 weeks). DEPO-PROVERA contains medroxyprogesterone acetate, a
chemical similar to (but not the same as) the natural hormone progesterone, which is produced
by your ovaries during the second half of your menstrual cycle. DEPO-PROVERA acts by
preventing your egg cells from ripening. If an egg is not released from the ovaries during your
menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROvERA
also causes changes in the lining of your uterus that make it less likely for pregnancy to occur
How effective is DEPO-PROVERA Contraceptive Injection?
The efficacy of DEPO-PROVERA Contraceptive Injection depends on following the
recommended dosage schedule exactly (see "How often do I get my shot of DEPO-PROVERA
Contraceptive Injection?"). To make sure you are not pregnant when you first get
DEPO-PROVERA Contraceptive Injection, your first injection must be given ONLY during
the first 5 days of a normal menstrual period; ONLY witnin the first 5 days after childbirth if not
breast-feeding; and, if exclusively breast-feeding, ONLY at the sixth week after childbirth. It is a
long-term injectable contraceptive when administered at 3-month (13-week) intervals.
DEPO-PROVERA Contraceptive Injection is over 99% effective, making it one of the most reliable
methods of birth control available. This means that the average annual pregnancy rate is less than
one for every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive
methods depends in part on how reliably each woman uses the method. The effectiveness of
DEPO-PROVERA depends only on the patient returning every 3 months (13 weeks) for her next
injection. Your health-care provider will help you compare DEPO-PROVERA with other
contraceptive methods and give you the information you need in order to decide which
contraceptive method is the right choice for you.
The following table shows the percent of women who got pregnant while using different kinds of
contraceptive methods. It gives both the lowest expected rate of pregnancy (the rate expected
in women who use each method exactly as it should be used) and the typical rate of pregnancy
(which includes women who became pregnant because they forgot to use their birth control or
because they did not follow the directions exactly).
Percent of Women Experiencing an Accidental Pregnancy
in the First Year of Continuous Use
Method
Lowest
Expected
Typical
DEPO-PROVERA
0.3
0.3
Implants (Norplant)
0.2*
0.2*
Female sterilization
0.2
0.4
Male sterilization
0.1
0.15
Oral contraceptive (pill)
3
Combined
0.1
Progestogen only
0.5
IUD
3
Progestasert
2.0
Copper T 380A
0.8
Condom (without spermicide)
2
12
Diaphragm (with spermicide)
6
18
Cervical cap
6
18
Withdrawal
4
18
Periodic abstinence
1-9
20
Spermicide alone
3
21
Vaginal Sponge
used before childbirth
6
18
used after childbirth
9
28
No method
as
85
Source: Trussell et al. Obstet Gynecol, 1990:76:558-567.
*From Norplant' package insert.
Who should not use DEPO-PROVERA Contraceptive Injection?
Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you have
any of the following conditions:
• if you think you might be pregnant
• if you have any vaginal bleeding without a known reason
B>irtR corvtrol ^ou-tKirxk aeout just H'xayear
•' if you have had cancer of the breast
• if you have had a stroke
• if you have or have had blood clots (phlebitis) in your legs
• if you have problems with your liver or liver disease
• if you are allergic to DEPO-PROVERA (medroxyprogesterone acetate or any of its other
ingredients).
What other things should I consider before using DEPO-PROVERA
Contraceptive Injection?
You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is
important to tell your health-care provider if you have any of the following:
• a family history of breast cancer
• an abnormal mammogram (breast x-ray), fibrocystic breast disease, breast nodules or lumps, or
bleeding from your nipples
• kidney disease
• irregular or scanty menstrual periods
• high blood pressure
• migraine headaches
• asthma
• epilepsy (convulsions or seizures)
• diabetes or a family history of diabetes
• a history of depression
• if you are taking any prescription or over-the-counter medications
This product is intended to prevent pregnancy. It does not protect against
transmission of HIV (AIDS) and other sexually transmitted diseases such as
chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
What if I want to become pregnant after using DEPO-PROVERA Contraceptive
Injection?
Because DEPO-PROVERA is a long-acting birth control method, it takes some time after your last
injection for its effect to wear off. Based on the results from a large study done in the United States,
for women who stop using DEPO-PROVERA in order to become pregnant, it is expected that
about half of those who become pregnant will do so in about 10 months after their last injection;
about two thirds of those who become pregnant will do so in about 12 months; about 83% of
those who become pregnant will do so in about 15 months; and about 93% of those who become
pregnant will do so in about 18 months after their last injection. The length of time you use
DEPO-PROVERA has no effect on how longit takes you to become pregnant after you stop using it
What are the risks of using DEPO-PROVERA Contraceptive Injection?
I .Irregular Menstrual Bleeding
The side effect reported most frequently by women who use DEPO-PROVERA for
contraception is a change in their normal menstrual cycle. During the first year of using
DEPO-PROVERA, you might have one or more of the following changes: irregular or
unpredictable bleeding or spotting, an increase or decrease in menstrual bleeding, or no bleeding
at all. Unusually heavy or continuous bleeding, however; is not a usual effect of DEPO-PROVERA;
and if this happens, you should see your health-care provider right away. With continued use of
DEPO-PROvERA, bleeding usually decreases, and many women stop having periods completely.
In clinical studies of DEPO-PROVERA, 55% of the.women studied reported no menstrual
bleeding (amenorrhea) after I year of use, and 68% of the women studied reported no menstrual
bleeding after 2 years of use. The reason that your periods stop is because DEPO-PROVERA
causes a resting state in your ovaries. When your ovaries do not release an egg monthly, the
regular monthly growth of the lining of your uterus does not occur and, therefore, the bleeding
that comes with your normal menstruation does not take place. When you stop using
DEPO-PROVERA your menstrual period will usually, in time, return to its normal cycle.
2. Bone Mineral Changes
Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral stored in
vour bones. This could increase your risk of developing bone fractures. The rate of bone mineral
loss is greatest in the early years of DEPO-PROVf RA use, but after that, it begins to resemble the
normal rate of age-related bone mineral loss.
3. Cancer
Studies of women who have used different forms of contraception found that women who used
DEPO-PROVERA for contraception had no increased overall risk of developing cancer of the
breast, ovary, uterus, cervix, or liver However women under 35 years of age wnose first exposure
to DEPO-PROVERA was within the previous 4 to 5 years may have a slightly increased risk of
developing breast cancer similar to that seen with oral contraceptives. You should discuss this with
your health-care provider
4. Unexpected Pregnancy
Because DEPO-PROvERA is such an effective contraceptive method, the risk of accidental
pregnancy for women who get their shots regularly (every 3 months [ 13 weeks]) is very low.
While there have been reports of an increased risk of low birth weight and neonatal infant death
or other health problems in infants conceived close to the time of injection, such pregnancies are
uncommon. If you think you may have become pregnant while using DEPO-PROVERA for
contraception, see your health-care provider as soon as possible.
SAIIergic Reactions
Some women using DEPO-PROVERA Contraceptive Injection have reported severe and
potentially life-threatening allergic reactions known as anaphylaxis and anaphylactoid reactions,
Symptoms include the sudden onset of hives or swelling and itching of the skin, breathing
difficulties, and a drop in blood pressure.
6.Other Risks
Women who use hormone-based contraceptives may have an increased risk of blood clots or
stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin
to develop outside of the uterus (ectopic pregnancy). While these events are rare, you should
tell your health-care provider if you have any of the problems listed in the next section.
What symptoms mav signal problems while using DEPO-PROVERA
Contraceptive Injection?
Call your health-care provider immediately if any of these problems occur following an injection
of DEPO-PROVERA:
• sharp chest pain, coughing up of blood, or sudden shortness of breath (indicating a possible clot
in the lung)
• sudden severe headache or vomiting, dizziness or fainting, problems with your eyesight or
speech, weakness, or numbness in an arm or leg (indicating a possible stroke)
• severe pain or swelling in the calf (indicating a possible clot in the leg)
• unusually heavy vaginal bleeding
• severe pain or tenderness in the lower abdominal area
• persistent pain, pus. or bleeding at the injection site
what are the possible side effects of DEPO-PROVERA Contraceptive Injection?
1. Weight Gain
You may experience a weight gain while you are using DEPO-PROVERA. About two thirds of
the women who used DEPO-PKOVERA in clinical trials reported a weight gain of about 5 pounds
during the first year of use. You mav continue to gain weight after the first year Women in one
large study who used DEPO-PROVERA for 2 years gained an average total of 8.1 pounds over
those 2 years, or approximately 4 pounds per year Women who continued for 4 years gained an
average total of 13.8 pounds over those 4 years, or approximately 3.5 pounds per year Women
who continued for 6 years gained an average total of 16.5 pounds over those 6 years, or
approximately 2.75 pounds per year
2. Other Side Effects
In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some
women reported the following effects that may or may not have been related to their use of
DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness, abdominal
cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps, nausea, vaginal
discharge or irritation, breast swelling and tenderness, bloating, swelling of the hands or feet,
backache, depression, insomnia, acne, pelvic pain, no hair growth or excessive hair loss, rash, hot
flashes, and joint pain. Other problems, were reported by very few of the women in the clinical
trials, but some of these could be serious. These include convulsions, jaundice, urinary tract
infections, allergic reactions, fainting, paralysis, osteoporosis, lack of return to fertility, deep vein
thrombosis, pulmonary embolus, breast cancer or cervical cancer If these or any other problems
occur during your use of DEPO-PROVERA, discuss them with your health-care provider
Should any precautions be followed during use of DEPO-PROVERA
Contraceptive Injection?
1. Missed Periods
During the time you are using DEPO-PROVERA for contraception, you may skip a period, or your
periods may stop completely. If you have been receiving your DEPO-PROVERA injections
regularly every 3 months (13 weeks), then you are probably not pregnant. However if you think
that you may be pregnant, see your health-care provider
2. Laboratory Test Interactions
If you are scheduled for any laboratory tests, tell your health-care provider that you are using
DEPO-PROVERA for contraception, Certain blood tests are affected by hormones such as
DEPO-PROVERA.
3. Drug Interactions
Cytadren (aminoglutethimide) is an anticancer drug that may significantly decrease the
effectiveness of DEPO-PROVERA if the two drugs are given during the same time.
4. Nursing Mothers
Although DEPO-PROVERA can be passed to the nursing infant in the breast milk, no harmful
effects nave been found in these children. DEPO-PROVERA does not prevent the breasts from
producing milk, so it can be used by nursing mothers. However to minimize the amount of
DEPO-PROVERA that is passed to the infant in the first weeks after birth, you should wait until
6 weeks after childbirth before you start using DEPO-PROVERA for contraception.
How often do I get my shot of DEPO-PROVERA Contraceptive Injection?
The recommended dose of DEPO-PROVERA is 150 mg every 3 months (13 weeks) given in a
single intramuscular injection in the buttock or upper arm. To make sure that you are not pregnant
at the time of the first injection, it is essential tnat the injection be given ONLY during the first
5 days of a normal menstrual period. If used following the delivery of a child, the first injection of
DEPO-PROVERA MUST be given within 5 days after childbirth if you are not breast-feeding or
6 weeks after childbirth if you are exclusively breast-feeding. If you wait longer than 3 months
(13 weeks) between injections, or longer than 6 weeks after delivery, your health-care provider
should determine that you are not pregnant before giving you your injection of DEPO-PROVERA.
Rx only CB-7-S
Pharmacia & Upjohn Company
Kalamazoo, Ml 49001, USA
Pharmacia
&Upjohn
NEWS IN BRIEF
Man sentenced for
border killings
CHIHUAHUA, Mexico - A court
upheld the conviction of an
Egyptian man for one of thefiiii
in a series of murders of womef
in the border city of Ciudaii
Juarez, but lowered the man's
prison sentence to 20 years.
The sentence for homicide
imposed Tuesday on Abdel Latif
Sharif by Judge Hecto:
Talamontes comes on the lOtf
anniversary of the first slayings
in 1993.
Since then, over 80 women
have been raped, murdered and
their bodies dumped in (lie
desert, in a case that has drawn
widespread criticism ol
Chihuahua state police for failing
to stop the eerily similar string
of crimes.
The number of victims has risen
in recent months, as more bodies
turn up. Police found the decom
posed remains of three women
earlier this month in Juarez.
Prosecutors wanted a toughei
sentence - like the 30 years
Sharif was originally sentenced
to, before his conviction was
overturned on appeal - arguing
that Sharif was responsible for
several murders, said Chihuahua
state spokesman Fernando
Medina.
But Judge Talamontes upheld
the lower court conviction onlyin
the 1995 murder of Elizabetli
Castro Garcia.
By Di
THE
The Texas
ketball team
toughest cl
when it meet
Jayhawks at /
Lawrence, Kc
The Jay he
year at home
three losses
Arizona, whr
1 in the natic
Florida, whicl
The Aggie
12) are 2-6 or
including a
69 loss to
Lubbock on 6
Senior gu
led the Aggie
the losing eff<
A&M He
Watkins said
game against
as tough as
game on the r
foccara Willia